Nonetheless, the critical importance of target specificity in CAR T cells was highlighted by the case report of severe off-tumour effects in a patient treated with a trastuzumab-based CAR [28], which targets a glycoepitope of HER2 [29]. The gene discussed is ERBB2; the disease is neoplasm.